The efficacy of continuing trastuzumab beyond progression for HER2-positive gastric cancer initially treated with a trastuzumab-containing regimen has been denied by a randomized trial (WJOG7112G), and it is not recommended (CQ25). This evidence concerns the gene ERBB2 and gastric cancer.